LinkagE between GAstrointestinal Symptom and CoronarY stenting study

LinkagE between GAstrointestinal Symptom and CoronarY stenting study - LEGACY study

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000011996

Enrollment

200

Registered

2013-10-10

Start date

2010-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary artery disease

Interventions

rabeprazole (PPI) vs placebo placebo

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: patients who undergoing coronary stent implantation within a month during dual anti platelet therapy evaluation by Global Overall Symptom(GOS) score > / = 4

Exclusion criteria

Exclusion criteria: allergy to rabeprazole severe liver, or renal dysfunction, heart failure, malignancy, gastroduodenal injury, taking warfarin,

Design outcomes

Primary

Measure	Time frame
to examine cardiovascular events, and gastrointestinal lesions at 1 month between rabeprazole and placebo groups	—

Countries

Japan

Contacts

Public ContactSeiji Hokimoto

Graduate School of Medical Sciences,Kumamoto University Department of Cardiovascular Medicine

shokimot@kumamoto-u.ac.jp096-373-5175

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026